In cancer, IDO has been demonstrated to block effective antitumor responses [21–24] by, e.g., arresting T-lymphocytes in G1 phase, promoting T-cell and dendritic cell apoptosis, and supporting regulatory T-cell generation [25–29]. Here, IDO1 is linked to cancer.